IGBA - International Generic and Biosimilar medicines Association

"A key priority for IGBA is to maintain patient access to medicines by advocating for the removal of trade barriers, including tariffs, that hinder the efficient supply and distribution of medicines across regional and international markets". Read IGBA’s position on trade barriers here: https://lnkd.in/e9ae7MXa

"A key priority for IGBA is to maintain patient access to medicines by advocating for the removal of trade barriers, including tariffs, that hinder the efficient supply and distribution of medicines across regional and international markets". Read IGBA’s position on trade barriers here: https://lnkd.in/e9ae7MXa

𝐁𝐢𝐨𝐬𝐢𝐦𝐢𝐥𝐚𝐫𝐬 𝐋𝐚𝐭𝐀𝐦 - 𝐂𝐨𝐥𝐨𝐦𝐛𝐢𝐚 𝟐𝟎𝟐𝟓 In-person Forum in Bogota on April 8, is focused on fostering greater access to #biosimilars in #Colombia. This forum gathers decision-makers from the pharmaceutical industry, regulatory bodies #INVIMA, #AEMPS, #DIGEMID, and associations to share success stories and actionable insights. With dynamic presentations, interactive panels, and networking opportunities, the forum emphasizes the strategic importance of vaccines and plasma-derived products. Discussions will cover recent regulatory advancements, strategies for self-sufficiency, and collaborations with leading institutions to build local biotech capabilities. 𝐊𝐞𝐲 𝐎𝐛𝐣𝐞𝐜𝐭𝐢𝐯𝐞𝐬: – Analyze recent regulatory and strategic advancements positioning Colombia on the biosimilars map, identifying areas for investment and alliances. – Examine the role of the industry in ensuring self-sufficiency in critical medicines, exploring government incentives and integration policies. – Investigate training programs in advanced skills and technology transfer through partnerships with leading Latin American institutions.   𝐅𝐞𝐚𝐭𝐮𝐫𝐞𝐝 𝐬𝐞𝐬𝐬𝐢𝐨𝐧𝐬: - Advanced Local Regulation: Unlocking the Potential of Biosimilars by Francisco Rossi, General Director at INVIMA (Colombia) - Strategies for the Consolidation of the Biosimilars Industry by Francisco Rossi - General Director at INVIMA (Colombia), Sol Ruiz - Head of Biologics, Advanced Therapies, and Biotechnology at AEMPS (Spain), Carolina Wiesner - General Director at National Cancer Institute (Colombia) - Redefining the Role of Industry in LATAM’s Health Autonomy by Indhira Bernuy - Executive Director of Pharmaceutical Products Directorate at DIGEMID (Peru), Adriana Robayo - Executive Director at IETS (Colombia) 📅 Date: April 8th 📍 Venue: CCB Cedritos, Bogota, Colombia The future of Biosimilars in Latin America and Colombia is in your hands! Register now and be part of this pivotal discussion! https://lnkd.in/gxbGi6uw Organized by JackLeckerman #BiosimilarsLatAm #Colombia2025 #Pharmaceuticals #LatinAmerica #Colombia #HealthcareInnovation #Biotech #JackLeckerman

If a complex disease can be treated through an affordable, quality-assured, safe, and effective medicine, patients might still not have access to it. Why? Partly because of IP system and market abuses. Do you want to learn more about this and what can be done? Read IGBA's Report on Intellectual Property and Competition here: https://lnkd.in/ew39ebGp #IP #IntellectualProperty #BalancedIPSystems #Competition

⌛ And It’s a Wrap-Up! 🎉 We concluded our day at the 3rd Bioequivalence Conference 2025. This afternoon, speakers shared valuable insights on compliance in #bioequivalence studies and discussed the latest developments on Good Clinical Practice (ICH E6). We also reflected on international convergence and how a single global development approach can impact patient access to quality-assured, safe, and effective medicines. #BIOEQ25 was a fantastic opportunity to support a science-based regulatory landscape for more equitable and timely access to medicines for patients around the world. 🌍 👏 Big thanks to all the participants! Let’s address together the healthcare challenges of today and tomorrow. ➡️ Check out our PR in collaboration with Medicines for Europe: https://lnkd.in/dRxWz6jY #BIOEQ25 #Bioequivalence #GlobalHealth Medicines for Europe, IGBA - International Generic and Biosimilar medicines Association Adrian van den Hoven, Beata Stepniewska, Trudy Beks, Cristina Romagnoli, Erika Zavan, Kate O'Regan, Indiana Castro Alonso, Susana Almeida, Nicolas Tascon G., Carlotta Cogoni

🌍 Greetings from Amsterdam! Today, we kicked off our Bioequivalence Conference 2025 in partnership with Medicines for Europe, addressing key questions on the international harmonisation of #bioequivalence. 📌 During Session 1, we covered the latest updates on ICH M13, including the current status, next steps for M13A implementation and key topics for M13C. 📌 Session 2 focused on Model-Informed Drug Development (MIDD), with fresh insights on ICH M15 and real-world examples of how companies are integrating model-informed approaches into their development processes. 🔄 Exciting times ahead for regulatory science and innovation! Stay tuned for more updates from #BIOEQ25! 📸 Swipe through to catch the speakers in action! #BIOEQ25 #Bioequivalence #GlobalHealth Medicines for Europe, IGBA - International Generic and Biosimilar medicines Association Adrian van den Hoven, Beata Stepniewska, Trudy Beks, Cristina Romagnoli, Erika Zavan, Kate O'Regan, Indiana Castro Alonso, Susana Almeida, Nicolas Tascon G., Carlotta Cogoni

#Patents that are genuine and protect a true innovation are valuable for society. On the contrary, patents designed and registered intending to block #generic or #biosimilar #competition are detrimental for #patients and for #healthcare budgets and represent an abuse of the patent system. For more information, we invite you to see IGBA's Report on Intellectual Property and Competition here: https://lnkd.in/ew39ebGp #IP #IntellectualProperty #BalancedIPSystems #Competition

Archana Jatkar and Sergio Napolitano, heads of our International Trade and IP Committee, presented IGBA's Report on IP and Competition during our launching webinar last Wednesday. If you want to see the full recording of our event, please click on this link: https://lnkd.in/etFjkaQV

Did you miss our webinar "Striving for Balanced IP Systems" where we launched our #IP and #Competition Report and discussed about what it takes to balance #innovation and #access to #medicines? You can watch it here: https://lnkd.in/etFjkaQV #IP #IntellectualProperty #BalancedIPSystems #Competition

🚨 𝐋𝐚𝐬𝐭 𝐂𝐡𝐚𝐧𝐜𝐞 𝐭𝐨 𝐑𝐞𝐠𝐢𝐬𝐭𝐞𝐫!🚨 Don’t miss the 𝟑𝐫𝐝 𝐁𝐢𝐨𝐞𝐪𝐮𝐢𝐯𝐚𝐥𝐞𝐧𝐜𝐞 𝐂𝐨𝐧𝐟𝐞𝐫𝐞𝐧𝐜𝐞 happening on 26 February 2025 in Amsterdam! 📍 This conference is a must-attend for regulators, industry leaders, and academics looking to gain unparalleled insights into the impact and opportunities of 𝐈𝐂𝐇 𝐌𝟏𝟑 𝐠𝐮𝐢𝐝𝐞𝐥𝐢𝐧𝐞𝐬, explore the latest bioequivalence guidelines, and discover advancements in 𝐬𝐢𝐧𝐠𝐥𝐞 𝐠𝐥𝐨𝐛𝐚𝐥 𝐝𝐞𝐯𝐞𝐥𝐨𝐩𝐦𝐞𝐧𝐭 and 𝐦𝐨𝐝𝐞𝐥-𝐢𝐧𝐟𝐨𝐫𝐦𝐞𝐝 𝐚𝐩𝐩𝐫𝐨𝐚𝐜𝐡𝐞𝐬 shaping the future of generic medicines. Let’s come together to align efforts for a harmonised future! 🌍 A heartfelt thank you to our sponsors ACDIMA BioCenter and AZIDUS LABORATORIES LTD, as well as our exhibitor Pharmaceutical Research Unit, for their generous support in making this event possible. 🙏 👉 Secure your spot now: https://buff.ly/3OMW98t 📋 Explore the full program: https://buff.ly/3ZKKnR8 #BIOEQ25 #Bioequivalence #GlobalHealth Medicines for Europe, IGBA - International Generic and Biosimilar medicines Association Adrian van den Hoven, Beata Stepniewska, Trudy Beks, Cristina Romagnoli, Erika Zavan, Kate O'Regan, Indiana Castro Alonso, Susana Almeida, Nicolas Tascon G., Carlotta Cogoni